The Early Coagulopathy for the Prognosis in Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-05

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this cohort study, the parameters (TM, TAT, PIC, tPAIC, et al.) associated with the hemostatic system will be collected in sepsis patients when admitted to the Intensive Critical Unit. Parameters will be evaluated for their prognostic function of 28 days mortality.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The object of this study is to find the early mortality prognostic biomarkers within the hemostatic system in sepsis patients. Blood samples will be collected from sepsis patients at admission. Parameters reflect endothelial injury, such as thrombomodulin (TM), tissue type plasminogen activator inhibitor complex (tPAIC), parameters reflect procoagulation condition, such as thrombin-antithrombin complex (TAT), and parameters reflect hyperfibrinolysis, such as plasmin-plasmin inhibitor complex (PIC) will be tested. Based on the results of these parameters, sepsis patients will be divided into coagulation parameter normal or abnormal groups. Twenty-eight days of mortality will be determined by patient follow-up. Regression analysis will be used to evaluate the relationship between these parameters and the mortality of sepsis patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Coagulopathy Outcome, Fatal

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Sepsis Thrombomodulin Thrombin-antithrombin complexe Plasmin-α2-plasmin inhibitor complex Tissue plasminogen activator-plasminogen activator inhibitor-1 complex Mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted to ICU of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from August 2020 to July 2022.
* Patients diagnosed with sepsis. The criteria for diagnosis is: 1. Infection or suspected infection; 2. SOFA score ≥ 2.
* Age interval: 18 years -- 80 years.
* Gender: unlimited.
* Signed informed consent form received.
* Results of the coagulation parameters tested within 24 hours after admission are available.

Exclusion Criteria

* Pregnant and lactating women.
* With primary diseases that can cause thrombocytopenia or prolong prothrombin time, such as leukemia.
* Patients with severe liver dysfunction.
* Patients with anticoagulation or fibrinolysis medications within 72 hours before admission.
* Patients are in a procoagulation condition, such as VTE patients, protein C or protein S deficient individuals.
* Patients with chronic renal failure.
* Patients need ECMO therapy.
* Patients with severe cardiopulmonary diseases or nervous system diseases.
* Patients at the end-stage of disease.
* Patients without signed informed consent forms.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hua-Qing Shu

Associated Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Huaqing Shu, Dr.

Role: CONTACT

Phone: ‭13437284416

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UHICU20201001

Identifier Type: -

Identifier Source: org_study_id